Visa Q3 Earnings Report

1 Mins read

Visa, the digital payments giant, is set to release its fiscal third-quarter earnings on Tuesday. Here are the key details you need to know:


In the quarter ended June 30, analysts expect Visa to report a profit of $4.36 billion, or $2.10 per share. This compares to a profit of $3.41 billion, or $1.60 per share, in the same quarter last year.

Adjusted Earnings

When excluding one-time items, FactSet anticipates adjusted earnings to be $2.11 per share.


Analysts project an increase in revenue to $8.06 billion, up from $7.28 billion in the year-ago period.

What to Watch


Investors will closely monitor Visa’s payments volume and total cross-border volume growth. In the same quarter last year, these figures rose by 12% and 40% respectively. This time, with higher interest rates and ongoing inflation concerns impacting consumer spending, the market will be paying attention to any changes.


The frequency of Visa card usage is another key metric to watch. Despite the possibility of reduced overall spending, investors will be interested in seeing if consumers continue to swipe their Visa cards as frequently as they did last quarter, when transactions were up 12%.


Wall Street will be eagerly waiting for any commentary from Visa’s management regarding consumer debt levels and default risks. As missed payment rates on car loans and credit-card debt increase, analysts will be curious to see if Visa addresses these concerns.

Related posts

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *